<qa>  What is the dose of Depakote-ER?Eligible subjects will complete baseline assessments and a 7-day run on Depakote-ER prior to randomization. After the 7-day baseline period and run in with Depakote-ER, subjects will be randomized and then transition to either 12 weeks of Depakote-ER or placebo, to begin upon completion of the 7-day run-in baseline period. Valproic acid level obtained at the end of the baseline period will be used to adjust the dose of Depakote-ER or matched placebo as needed to target a valproic level of 70-120 ugml. Dose increase, if needed, will occur with the study medication dispensed at the next follow up visit scheduled for the end of the 1st week of active study medication or placebo. Subjects with valproic acid levels 120 ugml at the end of the baseline period will be contacted as soon as possible and instructed to decrease their dose of Depakote-ER or matched placebo accordingly. Subjects randomized to the placebo condition will receive a placebo matched in number and appearance to the dosage of Depakote-ER prescribed during the 7-day baseline period. If needed, the number of placebo pills will be adjusted to match the change in the Depakote-ER dosage determined necessary based on the valproic acid level obtained at the end of the 7-day baseline period. 